These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

714 related items for PubMed ID: 29036231

  • 21. Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes.
    Landersdorfer CB, He YL, Jusko WJ.
    Br J Clin Pharmacol; 2012 Mar; 73(3):373-90. PubMed ID: 22442825
    [Abstract] [Full Text] [Related]

  • 22. The effects of dipeptidyl-peptidase-IV inhibitor, vildagliptin, on the exocrine pancreas in spontaneously diabetic Goto-Kakizaki rats.
    Mizukami H, Inaba W, Takahashi K, Kamata K, Tsuboi K, Yagihashi S.
    Pancreas; 2013 Jul; 42(5):786-94. PubMed ID: 23774700
    [Abstract] [Full Text] [Related]

  • 23. Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats.
    Maeda S, Yamagishi S, Matsui T, Nakashima S, Ojima A, Maeda S, Nishino Y, Ishibashi Y, Yoshida Y, Yamakawa R.
    Ophthalmic Res; 2013 Jul; 50(4):221-6. PubMed ID: 24081217
    [Abstract] [Full Text] [Related]

  • 24. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
    Akarte AS, Srinivasan BP, Gandhi S.
    Biochem Pharmacol; 2012 Jan 15; 83(2):241-52. PubMed ID: 22015634
    [Abstract] [Full Text] [Related]

  • 25. Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy.
    Bianchi R, Cervellini I, Porretta-Serapiglia C, Oggioni N, Burkey B, Ghezzi P, Cavaletti G, Lauria G.
    J Pharmacol Exp Ther; 2012 Jan 15; 340(1):64-72. PubMed ID: 21984837
    [Abstract] [Full Text] [Related]

  • 26. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients.
    Boschmann M, Engeli S, Dobberstein K, Budziarek P, Strauss A, Boehnke J, Sweep FC, Luft FC, He Y, Foley JE, Jordan J.
    J Clin Endocrinol Metab; 2009 Mar 15; 94(3):846-52. PubMed ID: 19088168
    [Abstract] [Full Text] [Related]

  • 27. Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats.
    Refaat R, Sakr A, Salama M, El Sarha A.
    Drug Dev Res; 2016 Sep 15; 77(6):300-9. PubMed ID: 27520857
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
    Ahrén B, Pacini G, Tura A, Foley JE, Schweizer A.
    Horm Metab Res; 2007 Nov 15; 39(11):826-9. PubMed ID: 17992639
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
    Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, Shao YM, Park TS.
    J Pharmacol Exp Ther; 2012 Feb 15; 340(2):248-55. PubMed ID: 22025647
    [Abstract] [Full Text] [Related]

  • 35. Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance and β-cell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet.
    Sato K, Nakamura A, Shirakawa J, Muraoka T, Togashi Y, Shinoda K, Orime K, Kubota N, Kadowaki T, Terauchi Y.
    Endocrinology; 2012 Mar 15; 153(3):1093-102. PubMed ID: 22315446
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.
    Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Deacon CF, Foley JE, Rizza RA, Camilleri M.
    Clin Endocrinol (Oxf); 2008 Nov 15; 69(5):737-44. PubMed ID: 18331607
    [Abstract] [Full Text] [Related]

  • 38. Effects of metformin, saxagliptin and repaglinide on gut microbiota in high-fat diet/streptozocin-induced type 2 diabetic mice.
    Tang Y, Yan M, Fang Z, Jin S, Xu T.
    BMJ Open Diabetes Res Care; 2024 May 06; 12(3):. PubMed ID: 38719505
    [Abstract] [Full Text] [Related]

  • 39. Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors.
    Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Hayakawa M, Shibasaki M.
    Pharmacol Rep; 2009 May 06; 61(5):899-908. PubMed ID: 19904014
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.